Search

Displaying results 3221 - 3230 of 10000 in total
  1. Target

    Hypoxia-inducible factor 1

    go.drugbank.com/bio_entities/BE0010297
    TargetHumans

    Forms heterodimers with the aryl hydrocarbon receptor (AHR) to mediate the transcriptional response to xenobiotics by binding xenobiotic response elements (XREs) or dioxin response elements (DREs) in target

    Polypeptides: Aryl hydrocarbon receptor nuclear translocatorSynonyms: Dioxin receptor, nuclear translocator
  2. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    Aglucosidase alfa consists of the human enzyme acid alpha-glucosidase (GAA) which is essential for the degradation of glygogen to glucose in lysosomes. … It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.

  3. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    [L54748] Developed through a collaboration involving the Global Antibiotic Research and Development Partnership (GARDP), zoliflodacin received approval from the U.S. … [A274938,L54748] It is indicated as a single-dose oral therapy for the treatment of uncomplicated urogenital gonorrhea.

  4. Drug

    Ethinamate

    go.drugbank.com/drugs/DB01031
    ApprovedIllicitWithdrawn

    Like many such similar medications, the regular use of ethinamate can result in the development of drug tolerance in a patient. … Ethinamate is a short-acting sedative-hypnotic medication used to treat insomnia.

  5. Drug

    Aminosalicylic acid

    go.drugbank.com/drugs/DB00233
    ApprovedInvestigational

    The sodium salt of the drug is better tolerated than the free acid.

  6. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Paritaprevir as a first line … Depending on the genotype, Paritaprevir is often used in combination with other antivirals such as [DB09296], [DB09183], [DB00503], and [DB00811], with the intent to cure, or achieve a sustained virologic

    Synonyms: (2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo
  7. Drug

    Inulin

    go.drugbank.com/drugs/DB00638
    ApprovedInvestigationalNutraceutical

    A starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan. … It has been used in physiologic investigation for determination of the rate of glomerular function.

  8. Drug

    Chlormezanone

    go.drugbank.com/drugs/DB01178
    ApprovedWithdrawn

    A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.

  9. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. … It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions.

    Categories: Adrenergic beta-1 Receptor Antagonists
  10. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors